CN1922205A - 甘丙肽受体与脑部损伤 - Google Patents

甘丙肽受体与脑部损伤 Download PDF

Info

Publication number
CN1922205A
CN1922205A CNA2005800051943A CN200580005194A CN1922205A CN 1922205 A CN1922205 A CN 1922205A CN A2005800051943 A CNA2005800051943 A CN A2005800051943A CN 200580005194 A CN200580005194 A CN 200580005194A CN 1922205 A CN1922205 A CN 1922205A
Authority
CN
China
Prior art keywords
galr2
pharmaceutical composition
composition according
damage
specific agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800051943A
Other languages
English (en)
Chinese (zh)
Inventor
D·温尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotargets Ltd
Original Assignee
Neurotargets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotargets Ltd filed Critical Neurotargets Ltd
Publication of CN1922205A publication Critical patent/CN1922205A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
CNA2005800051943A 2004-02-17 2005-01-18 甘丙肽受体与脑部损伤 Pending CN1922205A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0403509.3 2004-02-17
GBGB0403509.3A GB0403509D0 (en) 2004-02-17 2004-02-17 Galanin receptors and brain injury

Publications (1)

Publication Number Publication Date
CN1922205A true CN1922205A (zh) 2007-02-28

Family

ID=32039889

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800051943A Pending CN1922205A (zh) 2004-02-17 2005-01-18 甘丙肽受体与脑部损伤

Country Status (8)

Country Link
US (2) US20080020975A1 (https=)
EP (1) EP1723175A1 (https=)
JP (1) JP2008501632A (https=)
CN (1) CN1922205A (https=)
AU (1) AU2005214115B2 (https=)
CA (1) CA2555550A1 (https=)
GB (1) GB0403509D0 (https=)
WO (1) WO2005080427A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246502A (zh) * 2013-07-05 2016-01-13 复苏技术有限责任公司 用于防止或减少脑和全身再灌注损伤的保护液
CN106880837A (zh) * 2015-12-15 2017-06-23 北京脑重大疾病研究院 一种甘丙肽在制备防止缺血性脑卒的试剂中的应用
CN108348570A (zh) * 2015-11-30 2018-07-31 纽洛可科学有限公司 基于spexin的甘丙肽2型受体激动剂及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517930A (ja) 2004-10-21 2008-05-29 トランス テック ファーマ，インコーポレイテッド ＧａｌＲ１のアゴニストとしてのビススルホンアミド化合物、組成物、及び使用法
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
AU2008207287A1 (en) * 2007-01-19 2008-07-24 Howard Florey Institute Of Experimental Physiology And Medicine Use of galanin in a method of treating neurodegenerative diseases or conditions
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
KR101514440B1 (ko) * 2013-12-13 2015-04-22 고려대학교 산학협력단 갈라닌 수용체 3형의 리간드로서 스펙신의 용도
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
ES2707210B2 (es) * 2017-10-02 2020-09-30 Univ Malaga GAL(1-15) y análogos de la misma para uso en la prevención y/o tratamiento de trastornos y efectos relacionados con el alcohol.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU730137B2 (en) * 1996-01-24 2001-03-01 H. Lundbeck A/S DNA encoding galanin GALR2 receptors and uses thereof
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
AU3630297A (en) * 1996-07-24 1998-02-10 University Of Bristol, The Galanin
EP0948529A4 (en) * 1996-12-27 2002-09-25 Merck & Co Inc HUMAN GALANINE RECEPTOR GALR2 AND THE NUCLEIC ACID ENCODING IT.
US6337206B1 (en) * 1997-12-18 2002-01-08 Merck & Co., Inc. Nucleic acid encoding mouse galanin receptor (GALR2)
WO2002096934A1 (en) * 2001-05-25 2002-12-05 Kemia, Inc. Non-natural galanin receptor ligands

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246502A (zh) * 2013-07-05 2016-01-13 复苏技术有限责任公司 用于防止或减少脑和全身再灌注损伤的保护液
CN108348570A (zh) * 2015-11-30 2018-07-31 纽洛可科学有限公司 基于spexin的甘丙肽2型受体激动剂及其用途
CN108348570B (zh) * 2015-11-30 2022-05-03 纽洛可科学有限公司 基于spexin的甘丙肽2型受体激动剂及其用途
CN106880837A (zh) * 2015-12-15 2017-06-23 北京脑重大疾病研究院 一种甘丙肽在制备防止缺血性脑卒的试剂中的应用

Also Published As

Publication number Publication date
WO2005080427A1 (en) 2005-09-01
AU2005214115A1 (en) 2005-09-01
GB0403509D0 (en) 2004-03-24
US20100184638A1 (en) 2010-07-22
CA2555550A1 (en) 2005-09-01
JP2008501632A (ja) 2008-01-24
US20080020975A1 (en) 2008-01-24
AU2005214115B2 (en) 2010-08-12
EP1723175A1 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
US20100184638A1 (en) Galanin Receptors and Brain Injury
Francois et al. Dorsal-ventral patterning of the Drosophila embryo depends on a putative negative growth factor encoded by the short gastrulation gene.
JP3851653B2 (ja) ノッチタンパク質および核酸に基づいた治療および診断方法ならびに組成物
US5958709A (en) Processes for identifying compounds that bind to the human Y4 receptor
KR20050090420A (ko) 메타스틴 유도체 및 이의 용도
WO2000075655A1 (fr) Procede de criblage avec cd100
JP2002514055A (ja) ガラニンｇａｌｒ３受容体をコードするｄｎａおよびその使用
JP2000506392A (ja) 新規なヒト代謝指向型グルタミン酸レセプター
JPH10510709A (ja) 摂食行動を変える方法、該方法に有用な化合物、および視床下部の異型神経ペプチドｙ／ペプチドｙｙ受容体（ｙ５）をコードするｄｎａ
JP2000504107A (ja) ガラニンｇａｌｒ２受容体をコードするｄｎａおよびその使用
JP2002515003A (ja) 高親和性メラトニン受容体及びその使用
EP1554382B1 (en) Gpr54 knock-out mammals and screening methods using them
WO2000029441A1 (fr) Nouvelle proteine receptrice couplee a la proteine g, son adn et son ligand
JP2004538450A (ja) 神経系統障害及び生殖器官障害の治療法
US10335380B2 (en) Compounds suitable for the treatment of myeloproliferative neoplasms as well as methods for the diagnosis/prognosis of myeloproliferative neoplasms
WO2001098495A1 (fr) Nouvelle proteine et son adn
WO2001036633A1 (fr) Nouvelle proteine et son adn
JP4651893B2 (ja) 新規ポリペプチド、新規ｄｎａ、新規抗体および新規遺伝子改変動物
CA2456753A1 (en) Mammalian relaxin receptors
JPWO2001038529A1 (ja) 新規ポリペプチド、新規ｄｎａ、新規抗体および新規遺伝子改変動物
US20030176314A1 (en) Compounds for the treatment of pain
CN1255552C (zh) 体外检测crygs基因及其编码产物是否存在突变的方法
WO1998055141A1 (en) Methods and products for inducing apoptosis in neuroendocrine cells with macrophage stimulating protein
WO2004080485A1 (ja) 上部消化管疾患の予防・治療剤
WO2005100987A1 (ja) Ｇタンパク質共役型レセプタータンパク質の新規リガンドとその用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070228